Sanofi-Aventis' PCSK inhibitor Praluent is belatedly in the process of registering insurance benefits. It is slow compared to the rival drug Amgen's Repatha.

According to the industry on the 12th, Praluent (Alirocumab) was recently judged appropriate for benefit from the HIRA's Pharmaceutical Benefits Advisory Committee. It is a PCSK9 inhibitor and was first approved in Korea in January 2017. Since April of the same year, Repatha(Evolocumab) was approved and was first listed as an indication of HOFH (Homozygous Familial Hypercholesterolemia) in August 2018.

In January 2020 Repatha succeeded in expanding the benefit criteria to patients with ASCVD, atherosclerotic cardiovascular disease, H